253 related articles for article (PubMed ID: 33782837)
21. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
22. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
[TBL] [Abstract][Full Text] [Related]
23. The dosing and monitoring of vancomycin: what is the best way forward?
Drennan PG; Begg EJ; Gardiner SJ; Kirkpatrick CMJ; Chambers ST
Int J Antimicrob Agents; 2019 Apr; 53(4):401-407. PubMed ID: 30599240
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Nicasio AM; Bulitta JB; Lodise TP; D'Hondt RE; Kulawy R; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Feb; 56(2):682-6. PubMed ID: 22083484
[TBL] [Abstract][Full Text] [Related]
25. Area-Under-Curve-Guided Versus Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-Analysis.
Lim AS; Foo SHW; Benjamin Seng JJ; Magdeline Ng TT; Chng HT; Han Z
Ther Drug Monit; 2023 Aug; 45(4):519-532. PubMed ID: 36728329
[TBL] [Abstract][Full Text] [Related]
26. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus.
Jaruratanasirikul S; Julamanee J; Sudsai T; Saengsuwan P; Jullangkoon M; Ingviya N; Jarumanokul R
J Med Assoc Thai; 2010 Feb; 93(2):172-6. PubMed ID: 20301996
[TBL] [Abstract][Full Text] [Related]
27. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
28. Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?
Johnston MM; Huang V; Hall ST; Buckley MS; Bikin D; Barletta JF
Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115442. PubMed ID: 34192639
[TBL] [Abstract][Full Text] [Related]
29. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
30. Applicability of hemodialysis clearance parameter for vancomycin therapeutic drug monitoring during continuous hemodiafiltration in an infant.
Shiohira H; Isagawa S; Yamada S; Sunagawa S; Nakamatsu M; Yonaha F; Hokama N; Fujita J; Nakamura K
Pharmazie; 2018 Dec; 73(12):737-739. PubMed ID: 30522560
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling.
Gustavsen MT; Midtvedt K; Vethe NT; Robertsen I; Bergan S; Åsberg A
Ther Drug Monit; 2020 Jun; 42(3):407-414. PubMed ID: 31479042
[TBL] [Abstract][Full Text] [Related]
32. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
Yoo R; So H; Seo E; Kim M; Lee J
PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
[TBL] [Abstract][Full Text] [Related]
33. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
[TBL] [Abstract][Full Text] [Related]
34. Clinical application of vancomycin TDM in ventilated patients with gastrointestinal cancer: a propensity-matched analysis.
Zhang X; Wu Y; Wang D
BMC Infect Dis; 2024 Jan; 24(1):10. PubMed ID: 38166695
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Vancomycin TDM Strategies: Prediction and Prevention of Kidney Injuries Based on Vancomycin TDM Results.
Kim B; Hwang S; Heo E; Kim HS; Jung J; Kim ES; Kim HB; Lee K; Park JS; Song J; Lee JH; Chung JY; Song KH; Yoon S
J Korean Med Sci; 2023 Apr; 38(14):e101. PubMed ID: 37038640
[TBL] [Abstract][Full Text] [Related]
37. Association between vancomycin trough concentration and area under the concentration-time curve in neonates.
Frymoyer A; Hersh AL; El-Komy MH; Gaskari S; Su F; Drover DR; Van Meurs K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6454-61. PubMed ID: 25136027
[TBL] [Abstract][Full Text] [Related]
38. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
39. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
[TBL] [Abstract][Full Text] [Related]
40. A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin.
Ye ZK; Chen K; Chen YL; Zhai SD
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):469-472. PubMed ID: 27376822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
